CCM Pharma offers 525bp-550bp on euro TLB
CCM Pharma, the new pharmaceutical company that private equity group Cinven is forming by merging two of its recent acquisitions, has set price talk on its new £160m-equivalent euro-denominated term loan ‘B’ at 525bp-550bp.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
